ASCO Conference Coverage
Featured Articles
(BioPharma Dive) June 5, 2019 - An AstraZeneca cancer drug works best in people with an uncommon mutation. For a recent study evaluating whether the drug offered benefits to pancreatic cancer who have the mutation, researchers screened more than 3,300 patients. Only 247 of them tested positive, and even fewer participated in the...
Read Article
[ICR [UK]) June 5, 2019 - A pioneering gene-targeted drug already licensed for breast and ovarian cancer can benefit some men with prostate cancer, a major new clinical trial reports. Some 80 per cent of men with prostate cancer whose tumours had mutations in the BRCA breast cancer genes responded to olaparib. And even though men...
Read Article
Latest Articles
June 25, 2019
June 14, 2019
June 12, 2019
June 12, 2019
June 11, 2019
June 06, 2019
June 06, 2019
June 06, 2019
View More
News Commentary
Editor Image
05 Jun, 2019 | by H. Jack West, MD
While in keeping with what we see informally in our clinics, these documented...
View Comment
Editor Image
01 Jun, 2019 | by Tomasz M. Beer, MD
The TITAN study adds apalutamide to a growing number of agents that improve...
View Comment
View More
OBR Blog
Today, four plenary sessions dropped at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting featured... Read more
June 02, 2019
Several late-breaking studies made a splash today at the 2019 American Society of Clinical Oncology (ASCO) Annual... Read more
June 01, 2019

OBR Tweets

Apr 08
H. Jack West, MD: We have yet to see the results of the CheckMate-9LA trial, upon which this application is based,… https://t.co/QZIUuFK0ZP

Apr 03
Howard S. Hochster, MD: Interesting news on the KEYNOTE-177 first line MSI-H colon cancer trial. This is a 1:1 ran… https://t.co/Nx3Qp46jxN

Apr 01
Dean Gesme, MD: The reported low false positive rate in this large validation data set and high diagnostic acumen f… https://t.co/rGmVtpQ5lu

Mar 31
William McGivney, PhD: Kudos to CIGNA and to Humana and all those who helped drive the decisions of these two large… https://t.co/HF8BZCWGF7

Mar 30
H. Jack West, MD: This provides another option that is pretty much a lateral move compared to atezolizumab with che… https://t.co/hnkRD0AfXw

Mar 26
Howard S. Hochster, MD: There is no question that SARS-CoV-2 will prove to be a major challenge to all health care… https://t.co/EyJijktM68

Mar 25
OBR speaks to providers at community oncology practices like Florida Cancer Specialists & Research Institute (FCS)… https://t.co/3qyne3w9gE

Mar 25
Dr. David Penson of Vanderbilt University Medical Center @VUmedicine delves into Financial toxicity and its negativ… https://t.co/o2IUnKvcff

Mar 25
Dr. Azra Raza @AzraRazaMD, an Oncologist at @Columbia, speaks to us about her recently published book @thefirstcell… https://t.co/x1HmTvHta7

Mar 25
H. Jack West, MD: An excellent piece that highlights what the history of cancer research should be teaching the wor… https://t.co/QAEpZJP8ov